- Home
- DAVA vs RAPT Comparison
DAVA vs RAPT Comparison
Compare DAVA & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVA
- RAPT
- Stock Information
- Founded
- DAVA 2000
- RAPT 2015
- Country
- DAVA United Kingdom
- RAPT United States
- Employees
- DAVA N/A
- RAPT N/A
- Industry
- DAVA EDP Services
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- DAVA Technology
- RAPT Health Care
- Exchange
- DAVA Nasdaq
- RAPT Nasdaq
- Market Cap
- DAVA 503.6M
- RAPT 498.4M
- IPO Year
- DAVA 2018
- RAPT 2019
- Fundamental
- Price
- DAVA $6.58
- RAPT $28.83
- Analyst Decision
- DAVA Buy
- RAPT Strong Buy
- Analyst Count
- DAVA 8
- RAPT 9
- Target Price
- DAVA $18.14
- RAPT $57.00
- AVG Volume (30 Days)
- DAVA 1.3M
- RAPT 778.5K
- Earning Date
- DAVA 11-11-2025
- RAPT 11-06-2025
- Dividend Yield
- DAVA N/A
- RAPT N/A
- EPS Growth
- DAVA 58.26
- RAPT N/A
- EPS
- DAVA 0.25
- RAPT N/A
- Revenue
- DAVA $1,015,391,026.00
- RAPT N/A
- Revenue This Year
- DAVA N/A
- RAPT N/A
- Revenue Next Year
- DAVA $3.81
- RAPT N/A
- P/E Ratio
- DAVA $25.81
- RAPT N/A
- Revenue Growth
- DAVA 1.07
- RAPT N/A
- 52 Week Low
- DAVA $6.52
- RAPT $5.67
- 52 Week High
- DAVA $34.94
- RAPT $42.39
- Technical
- Relative Strength Index (RSI)
- DAVA 29.78
- RAPT 53.26
- Support Level
- DAVA $6.64
- RAPT $27.76
- Resistance Level
- DAVA $7.36
- RAPT $29.90
- Average True Range (ATR)
- DAVA 0.44
- RAPT 1.66
- MACD
- DAVA -0.24
- RAPT -0.46
- Stochastic Oscillator
- DAVA 0.74
- RAPT 41.72
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.